States face lobbying from drugmakers to restrict biosimilars

01/29/2013 | New York Times (tiered subscription model), The

Amgen and Genentech are among the drugmakers pushing state legislatures to restrict substitution of biosimilar drugs for branded biologic therapies. Bills under consideration would require patient consent and doctor notification before a biosimilar may be substituted and would mandate that only drugs deemed "interchangeable" by the FDA could be substituted.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ